![Helena Tayton-Martin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Helena Tayton-Martin
Directeur Général chez
EVAXION A/S
Fortune : 914 460 $ au 31/05/2026
Profil
Helena Katrina Tayton-Martin was the founder of Avidex Ltd. (founded in 2008) and served as Chief Operating Officer from 2008 to 2017.
Dr. Tayton-Martin was the founder of Adaptimmune Ltd. (founded in 2008) and served as Chief Operating Officer from 2008 to 2025.
Dr. Tayton-Martin was the founder of Adaptimmune LLC (founded in 2011) and served as Director from 2011 to 2014.
Dr. Tayton-Martin was the founder of Adaptimmune Therapeutics Plc (founded in 2008) and served as Chief Business & Strategy Officer from 2022 to 2025.
The current job is Chief Executive Officer at Evaxion AS starting in 2025.
Former jobs include Independent Director at Trillium Therapeutics, Inc. from 2017 to 2021, Senior Business Development Officer at Medigene, Inc., Associate at Chiltern International Ltd., Associate-Clinical Projects UK at Pasteur Mérieux Connaught, Member at GSK Plc, and Member at Roche Group.
Education includes an MBA from London Business School, a doctorate from the University of Bristol conferred in 1992, and an undergraduate degree from The University of Reading conferred in 1985.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EVAXION A/S 0,55 % | 18/03/2026 | 2 286 150 ( 0,55 % ) | 914 460 $ | 31/05/2026 |
Postes actifs de Helena Tayton-Martin
| Sociétés | Poste | Début |
|---|---|---|
| EVAXION A/S | Directeur Général | 24/11/2025 |
Anciens postes connus de Helena Tayton-Martin
| Sociétés | Poste | Fin |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Fondateur | 31/03/2025 |
Adaptimmune Ltd.
 Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Focuses on the use of T cell therapy to treat cancer and infectious diseases | Fondateur | 01/03/2025 |
| TRILLIUM THERAPEUTICS | Directeur/Membre du Conseil | 17/11/2021 |
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers drugs for the treatment of cancer and autoimmune diseases | Fondateur | 01/01/2017 |
Adaptimmune LLC
 Adaptimmune LLC Medical/Nursing ServicesHealth Services Focuses on the use of T cell therapy to treat cancer and infectious disease | Fondateur | 01/01/2014 |
Formation de Helena Tayton-Martin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
53
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
MediGene, Inc.
 MediGene, Inc. Pharmaceuticals: MajorHealth Technology Develops herpes simplex virus technologies for the treatment of tumors and for gene delivery | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers drugs for the treatment of cancer and autoimmune diseases | Health Technology |
The University of Reading
 The University of Reading Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Bristol
 University of Bristol Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
London Business School
 London Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chiltern International Ltd.
 Chiltern International Ltd. Miscellaneous Commercial ServicesCommercial Services Provides clinical research services | Commercial Services |
Pasteur Mérieux Connaught | |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Focuses on the use of T cell therapy to treat cancer and infectious diseases | Health Services |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Focuses on the use of T cell therapy to treat cancer and infectious disease | Health Services |
Adaptimmune Therapeutics Plc
 Adaptimmune Therapeutics Plc BiotechnologyHealth Technology Manufactures vaccines and cancer immunotherapy products | Health Technology |
Evaxion Biotech A/S
 Evaxion Biotech A/S BiotechnologyHealth Technology Develops novel vaccines | Health Technology |
